Microsoft word - jessel, abstract clinam.doc
Nanostructured and Multilayered Active Materials for Clinical Applications S. FACCA1, A. DIERICH2, J.-C. VOEGEL1, N. BENKIRANE-JESSEL1
1Institut National de la Santé et de la Recherche Médicale, Unité 977, Faculté de Médecine, 11 rue Humann, 67085, Strasbourg Cedex, France and Faculté de Chirurgie Dentaire, UDS, Strasbourg 2Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut Clinique de la Souris (ICS), CNRS/INSERM/ULP, Collège de France, BP 10142, Strasbourg, France. Contact : [email protected]
In recent years, considerable effort has been devoted to the design and controlled
fabrication of structured materials with functional properties. The layer by layer buildup of polyelectrolyte multilayer films (PEM films) from oppositely charged polyelectrolytes1
offers new opportunities for the preparation of functionalized biomaterial coatings. This technique allows the preparation of supramolecular nano-architectures exhibiting specific properties in terms of control of cell activation and may also play a role in the
development of local drug delivery systems. Peptides, proteins or DNA, chemically bound to polyelectrolytes, adsorbed or embedded in PEM films, have been shown to retain their
Recently, tissue engineering has merged with stem cell technology with interest to develop new sources of transplantable material for injury or disease treatment. Eminently
interesting, are bone and joint injuries disorders because of the low self-regenerating capacity of the matrix secreting cells. We present here for the first time that embedded
BMP-2 and TGFβ1 in a multilayered polyelectrolyte film can drive embryonic stem cells to
the cartilage or bone differentiation depending on supplementary co-factors. We selected
a model system made from layer by layer poly-ℓ-glutamic acid (PℓGA) and poly-ℓ-lysine succinylated (PℓLs) films into which BMP-2 and TGFβ1 have been embedded. Our results
demonstrate clearly that we are able to induce osteogenesis in embryonic stem cells
mediated by growth factors embedded in a polyelectrolyte multilayer film9.
. Decher, G. Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science
1237 (1997) 2
. Jessel, N. et al. Bioactive coatings based on a polyelectrolyte multilayer architecture functionalized
by embedded proteins. Adv. Mater.
15, 692-695 (2003) 3
. Jessel, N. et al. Build-up of polypeptide multilayer coatings with anti-inflammatory properties based
on the embedding of piroxicam-cyclodextrin complexes. Adv. Funct. Mater.
14, 174-182 (2004) 4
. Jessel, N. et al. Pyridylamino-beta-cyclodextrin as a molecular chaperone for lipopolysaccharide
embedded in a multilayered polyelectrolyte architecture. Adv. Funct. Mater
. 14, 963-969 (2004) 5
. Jessel, N. et al. Control of monocyte morphology on and response to model surfaces for implants
equipped with anti-inflammatory agents. Adv. Mater.
16, 1507-1511 (2004) 6
. Jessel, N. et al. Short-time tuning of the biological activity of functionalized polyelectrolyte. Adv.
15, 648-654 (2005) 7
. Jessel, N. et al. Multiple and time scheduled in situ DNA delivery mediated by β-cyclodextrin
embedded in a polyelectrolyte multilayer. Proc. Natl. Acad. Sci (USA).
103, 8618-8621 (2006) 8
. Zhang, X. et al. Transfection Ability and Intracellular DNA Pathway of Nanostructured Gene-Delivery
13, 8, 2432-2436 (2008) 9
. Dierich, A et al. Bone formation mediated by growth factors embedded in a polyelectrolyte multilayer
film. Adv. Mater
Patient Information and Medical History Patient Name ____________________ SSN ____________________________ Birth date ______________________ Phone Number _______________________________ THE FOLLOWING INFORMATION IS CONFIDENTIAL. List all Medications which you If you have any allergies, currently use and why: please list them and your reaction here: (ex.
Low-Dose Naltrexone (LDN) for Mood Regulation and Immunomodulation in ASD Jaquelyn McCandless, M.D., April 2006 Naltrexone is a medication used as an opiate antagonist for treating opiate drug and alcohol addiction since the 1970s, FDA-approved since 1985 and now available in generic form as well as in the brand name ReVia in 50mg tablets. At regular dosing to treat addiction,